Malwina Suszynska
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Malwina Suszynska has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Paulina Galka-Marciniak
Institute of Bioorganic Chemistry, Polish Academy of Sciences, Poznan, Poland
20 shared publications - Piotr Kozlowski
Institute of Bioorganic Chemistry, Polish Academy of Sciences, Poznan, Poland
20 shared publications Aleksandra Ryszkowska
18 shared publications- Anna Jasiak
Department of Biology and Medical Genetics, Medical University of Gdańsk, Gdańsk, Poland
18 shared publications - Bartosz Wasag
Medical University of Gdansk, Gdansk, Poland
18 shared publications - Cezary Cybulski
Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, ul. Unii Lubelskiej 1, 71-252 Szczecin, Poland
18 shared publications
Latest Publications
- Open Access
- 19 June 2026
- Published by Springer Nature in npj Genomic Medicine
- Vol. 11 (1)
BCL2 promoter region mutations are an independent marker of BCL2 level in lymphoid malignancies
BCL2 upregulation is a key driver of lymphomagenesis and treatment response. By analyzing large-scale whole-genome datasets, we identify a lymphoma-specific noncoding mutational hotspot encompassing the BCL2 promoter that, independent of other factors such as the t(14;18) translocation, strongly associates with allele-specific BCL2 upregulation. These mutations disrupt regulatory protein-binding sites, alter BCL2 isoform balance, and associate with worse survival in diffuse large B-cell lymphoma.
- 19 June 2026
- Published by Springer Nature in npj Genomic Medicine
- Vol. 11 (1)
Open AccessBCL2 promoter region mutations are an independent marker of BCL2 level in lymphoid malignancies
BCL2 upregulation is a key driver of lymphomagenesis and treatment response. By analyzing large-scale whole-genome datasets, we identify a lymphoma-specific noncoding mutational hotspot encompassing the BCL2 promoter that, independent of other factors such as the t(14;18) translocation, strongly associates with allele-specific BCL2 upregulation. These mutations disrupt regulatory protein-binding sites, alter BCL2 isoform balance, and associate with worse survival in diffuse large B-cell lymphoma.
- Open Access
- 20 February 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (8) , eaea6079
miRNA gene mutations commonly disrupt the proper functioning of miRNA genes
A growing number of mutations are being identified in the noncoding genome, including microRNA (miRNA) genes; however, little is known about the consequences of these mutations and how harmful they are to the functioning of miRNA genes. To evaluate the effects of miRNA gene mutations, we took advantage of a large collection of somatic mutations identified in miRNA genes in >10,000 The Cancer Genome Atlas cancer samples and compared them with the corresponding miRNA sequencing data. Using different analytical approaches and rigorous statistical criteria, we revealed that a substantial fraction of mutations is deleterious for the proper functioning of miRNA genes affecting the level of mature miRNAs, isomiR profiles (precision of DROSHA/DICER1 cleavage), and/or 5p/3p miRNA strand balance. We also showed that most mutations, especially those identified as deleterious, destabilize the structure of miRNA precursors. The analysis showed that many miRNA gene mutations can damage miRNA genes and, if located in disease-related miRNA genes, may be pathogenic variants.
- 20 February 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (8) , eaea6079
Open AccessmiRNA gene mutations commonly disrupt the proper functioning of miRNA genes
A growing number of mutations are being identified in the noncoding genome, including microRNA (miRNA) genes; however, little is known about the consequences of these mutations and how harmful they are to the functioning of miRNA genes. To evaluate the effects of miRNA gene mutations, we took advantage of a large collection of somatic mutations identified in miRNA genes in >10,000 The Cancer Genome Atlas cancer samples and compared them with the corresponding miRNA sequencing data. Using different analytical approaches and rigorous statistical criteria, we revealed that a substantial fraction of mutations is deleterious for the proper functioning of miRNA genes affecting the level of mature miRNAs, isomiR profiles (precision of DROSHA/DICER1 cleavage), and/or 5p/3p miRNA strand balance. We also showed that most mutations, especially those identified as deleterious, destabilize the structure of miRNA precursors. The analysis showed that many miRNA gene mutations can damage miRNA genes and, if located in disease-related miRNA genes, may be pathogenic variants.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Variant Identification in BARD1, PRDM9, RCC1, and RECQL in Patients with Ovarian Cancer by Targeted Next-generation Sequencing of DNA Pools
Several ovarian cancer susceptibility genes have been discovered, but more are likely to exist. In this study, we aimed to analyze knowledge-based selected genes, that is, BARD1, PRDM9, RCC1, and RECQL, in which pathogenic germline variants have been reported in patients with breast and/or ovarian cancer. As deep sequencing of DNA samples remains costly, targeted next-generation sequencing of DNA pools was utilized to screen the exons of BARD1, PRDM9, RCC1, and RECQL in approximately 400 Polish ovarian cancer cases. A total of 25 pools of 16 samples (including several duplicated samples with known variants) were sequenced on the NovaSeq6000 and analyzed with SureCall (Agilent) application. The set of variants was filtrated to exclude spurious variants, and, subsequently, the identified rare genetic variants were validated using Sanger sequencing. No pathogenic mutation was found within the analyzed cohort of patients with ovarian cancer. Validation genotyping of filtered rare silent and missense variants revealed that the majority of them were true alterations, especially those with a higher mutation quality value. The high concordance (R2 = 0.95) of population allele frequency for 44 common SNPs in the European control population (gnomAD) and our experiment confirmed the reliability of pooled sequencing. Mutations in BARD1, PRDM9, RCC1, and RECQL do not contribute substantially to the risk of ovarian cancer. Pooled DNA sequencing is a cost-effective and reliable method for the initial screening of candidate genes; however, it still requires validation of identified rare variants.Prevention Relevance:BARD1, PRDM9, RCC1, and RECQL are not high/moderate-risk ovarian cancer susceptibility genes. Pooled sequencing is a reliable and cost-effective method to detect rare variants in candidate genes.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Variant Identification in BARD1, PRDM9, RCC1, and RECQL in Patients with Ovarian Cancer by Targeted Next-generation Sequencing of DNA Pools
Several ovarian cancer susceptibility genes have been discovered, but more are likely to exist. In this study, we aimed to analyze knowledge-based selected genes, that is, BARD1, PRDM9, RCC1, and RECQL, in which pathogenic germline variants have been reported in patients with breast and/or ovarian cancer. As deep sequencing of DNA samples remains costly, targeted next-generation sequencing of DNA pools was utilized to screen the exons of BARD1, PRDM9, RCC1, and RECQL in approximately 400 Polish ovarian cancer cases. A total of 25 pools of 16 samples (including several duplicated samples with known variants) were sequenced on the NovaSeq6000 and analyzed with SureCall (Agilent) application. The set of variants was filtrated to exclude spurious variants, and, subsequently, the identified rare genetic variants were validated using Sanger sequencing. No pathogenic mutation was found within the analyzed cohort of patients with ovarian cancer. Validation genotyping of filtered rare silent and missense variants revealed that the majority of them were true alterations, especially those with a higher mutation quality value. The high concordance (R2 = 0.95) of population allele frequency for 44 common SNPs in the European control population (gnomAD) and our experiment confirmed the reliability of pooled sequencing. Mutations in BARD1, PRDM9, RCC1, and RECQL do not contribute substantially to the risk of ovarian cancer. Pooled DNA sequencing is a cost-effective and reliable method for the initial screening of candidate genes; however, it still requires validation of identified rare variants.Prevention Relevance:BARD1, PRDM9, RCC1, and RECQL are not high/moderate-risk ovarian cancer susceptibility genes. Pooled sequencing is a reliable and cost-effective method to detect rare variants in candidate genes.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table from Variant Identification in BARD1, PRDM9, RCC1, and RECQL in Patients with Ovarian Cancer by Targeted Next-generation Sequencing of DNA Pools
Supplementary Table from Variant Identification in BARD1, PRDM9, RCC1, and RECQL in Patients with Ovarian Cancer by Targeted Next-generation Sequencing of DNA Pools
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table from Variant Identification in BARD1, PRDM9, RCC1, and RECQL in Patients with Ovarian Cancer by Targeted Next-generation Sequencing of DNA Pools
Supplementary Table from Variant Identification in BARD1, PRDM9, RCC1, and RECQL in Patients with Ovarian Cancer by Targeted Next-generation Sequencing of DNA Pools